Pharmaceutical Mail. 60 percent of hospital pharmaceutical spending in Spain in 2015 corresponded to original biologics (3.600 million euros), while only eighty million went to biosimilars. In 2020, as pointed out last week by the general director of the employers' association Biosim, Ángel Luis Rodríguez de la Cuerda, the hospital bill for biosimilars could reach 1.500 million euros thanks to patent expirations. Another 2.800 would go to branded biologics and 1.700 to chemically synthesized molecules. But whether or not these figures come true would depend on the Administration's commitment to the biosimilar, and more specifically, on its pricing system.

READ MORE